Mar 15, 2012, 05.57PM IST
Having won a landmark decision, Natco Pharma is collecting data to identify other life saving drugs where they can apply for compulsory licensing. The company chose Bayer’s drug Nexavar as the price of the original drug of Rs 2.84 lakh for a month’s dosage was unaffordable for local patients.
Rajeev Nannapaneni, CEO of Natco Pharma, tells ET that the grant of the country’s first compulsory licensing on Monday will trigger more such applications from Indian firms. Excerpts from an interaction